2. MID-LEVEL RESEARCHER AT A SMALL BIOTECH

Related Articles Minding your $ and ¢ 1. FIRST-YEAR POSTDOC AT A LARGE UNIVERSITY 3. DIRECTOR OF TOXICOLOGY AT A LARGE PHARMACEUTICAL COMPANY 4. RESEARCHER AT THE US FOOD AND DRUG ADMINISTRATION Economic Status: This 34-year-old woman has been at her company for five years, makes $90,000 a year, and has saved $40,000 in a 401(k). Her husband makes $60,000 a year and has saved about $20,000 in his 401(k). They have one four-year-old child and are planning to have another wit

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Economic Status: This 34-year-old woman has been at her company for five years, makes $90,000 a year, and has saved $40,000 in a 401(k). Her husband makes $60,000 a year and has saved about $20,000 in his 401(k). They have one four-year-old child and are planning to have another within a year.

Financial Considerations: Being prepared for high turnover at biotechs, planning for retirement, saving for college, on a comfortable joint income.

Goals: Focus on retirement: Hal Schweiger, a financial planner with Capital Financial Advisers in San Diego, says that the couple can retire in 30 years with about $5.6 million if they both maximize contributions to their 401(k) plans. To buffer against the inherent uncertainty of working in the biotech sector, Schweiger recommends building up an emergency fund equivalent to six month's salary in something like a money market account.

The Plan: Maximizing her 401(k) contribution means contributing eight ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies